SG11202113167QA - Fused heterocyclic derivatives - Google Patents
Fused heterocyclic derivativesInfo
- Publication number
- SG11202113167QA SG11202113167QA SG11202113167QA SG11202113167QA SG11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA SG 11202113167Q A SG11202113167Q A SG 11202113167QA
- Authority
- SG
- Singapore
- Prior art keywords
- compound
- formula
- membered monocyclic
- hbv
- mmol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853533P | 2019-05-28 | 2019-05-28 | |
| EP19176933 | 2019-05-28 | ||
| CN2020085720 | 2020-04-20 | ||
| PCT/US2020/034643 WO2020243135A1 (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202113167QA true SG11202113167QA (en) | 2021-12-30 |
Family
ID=71741889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202113167QA SG11202113167QA (en) | 2019-05-28 | 2020-05-27 | Fused heterocyclic derivatives |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP3976617B1 (https=) |
| JP (1) | JP2022535734A (https=) |
| KR (1) | KR20220012913A (https=) |
| CN (1) | CN113906028A (https=) |
| AU (1) | AU2020285718A1 (https=) |
| BR (1) | BR112021022889A8 (https=) |
| CA (1) | CA3138168A1 (https=) |
| CL (1) | CL2021003155A1 (https=) |
| CO (1) | CO2021016433A2 (https=) |
| CR (1) | CR20210666A (https=) |
| DO (1) | DOP2021000230A (https=) |
| IL (1) | IL288322A (https=) |
| JO (1) | JOP20210313A1 (https=) |
| MA (1) | MA56043A (https=) |
| MX (1) | MX2021014575A (https=) |
| PE (1) | PE20220767A1 (https=) |
| PH (1) | PH12021552974A1 (https=) |
| SG (1) | SG11202113167QA (https=) |
| WO (1) | WO2020243135A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116744927A (zh) * | 2020-12-02 | 2023-09-12 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物及其在治疗hbv感染中的用途 |
| WO2022116999A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives and their use in the treatment of hbv infection |
| WO2022116998A1 (en) * | 2020-12-02 | 2022-06-09 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives as hbv inhibitors |
| WO2022253255A1 (en) * | 2021-06-02 | 2022-12-08 | Janssen Sciences Ireland Unlimited Company | Fused heterocyclic derivatives |
| CN117715909A (zh) | 2021-06-02 | 2024-03-15 | 杨森科学爱尔兰无限公司 | 稠合杂环衍生物 |
| WO2024114709A1 (en) * | 2022-12-01 | 2024-06-06 | Janssen Sciences Ireland Unlimited Company | A crystal form of a fused heterocycle derivative compound |
| WO2024140851A1 (zh) * | 2022-12-28 | 2024-07-04 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2993174A1 (en) * | 2014-09-08 | 2016-03-09 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH | Pyrazolopyridine derivatives and their use in therapy |
| RU2742305C2 (ru) * | 2014-12-30 | 2021-02-04 | Новира Терапьютикс, Инк. | Производные и способы лечения инфекций гепатита в |
| AU2017290755B2 (en) * | 2016-06-29 | 2021-07-01 | Novira Therapeutics, Inc. | Diazepinone derivatives and their use in the treatment of hepatitis B infections |
| JP6935434B2 (ja) * | 2016-06-29 | 2021-09-15 | ノヴィラ・セラピューティクス・インコーポレイテッド | オキサジアゼピノン誘導体及びｂ型肝炎感染症の治療におけるその使用 |
| SG11202111236UA (en) * | 2019-04-30 | 2021-11-29 | Aicuris Gmbh & Co Kg | Novel indole-2-carboxamides active against the hepatitis b virus (hbv) |
-
2020
- 2020-05-27 WO PCT/US2020/034643 patent/WO2020243135A1/en not_active Ceased
- 2020-05-27 KR KR1020217042210A patent/KR20220012913A/ko not_active Withdrawn
- 2020-05-27 AU AU2020285718A patent/AU2020285718A1/en not_active Abandoned
- 2020-05-27 MA MA056043A patent/MA56043A/fr unknown
- 2020-05-27 CR CR20210666A patent/CR20210666A/es unknown
- 2020-05-27 PH PH1/2021/552974A patent/PH12021552974A1/en unknown
- 2020-05-27 BR BR112021022889A patent/BR112021022889A8/pt unknown
- 2020-05-27 SG SG11202113167QA patent/SG11202113167QA/en unknown
- 2020-05-27 EP EP20744199.9A patent/EP3976617B1/en active Active
- 2020-05-27 CN CN202080039617.8A patent/CN113906028A/zh active Pending
- 2020-05-27 PE PE2021001959A patent/PE20220767A1/es unknown
- 2020-05-27 JP JP2021570274A patent/JP2022535734A/ja active Pending
- 2020-05-27 CA CA3138168A patent/CA3138168A1/en active Pending
- 2020-05-27 MX MX2021014575A patent/MX2021014575A/es unknown
-
2021
- 2021-11-05 DO DO2021000230A patent/DOP2021000230A/es unknown
- 2021-11-23 IL IL288322A patent/IL288322A/en unknown
- 2021-11-25 JO JOP/2021/0313A patent/JOP20210313A1/ar unknown
- 2021-11-26 CL CL2021003155A patent/CL2021003155A1/es unknown
- 2021-12-01 CO CONC2021/0016433A patent/CO2021016433A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020243135A1 (en) | 2020-12-03 |
| EP3976617B1 (en) | 2025-04-23 |
| BR112021022889A2 (pt) | 2022-01-04 |
| PE20220767A1 (es) | 2022-05-16 |
| CR20210666A (es) | 2022-03-11 |
| PH12021552974A1 (en) | 2022-07-11 |
| DOP2021000230A (es) | 2022-05-31 |
| EP3976617A1 (en) | 2022-04-06 |
| CA3138168A1 (en) | 2020-12-03 |
| CO2021016433A2 (es) | 2021-12-10 |
| BR112021022889A8 (pt) | 2024-03-05 |
| CL2021003155A1 (es) | 2022-07-22 |
| JP2022535734A (ja) | 2022-08-10 |
| MA56043A (fr) | 2022-04-06 |
| MX2021014575A (es) | 2022-05-24 |
| CN113906028A (zh) | 2022-01-07 |
| JOP20210313A1 (ar) | 2021-11-25 |
| AU2020285718A1 (en) | 2022-02-03 |
| IL288322A (en) | 2022-01-01 |
| KR20220012913A (ko) | 2022-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3976617B1 (en) | Fused heterocyclic derivatives | |
| US20230076319A1 (en) | Inhibitors of hepatitis b virus | |
| CN111511747A (zh) | 用于治疗与hbv感染相关的疾病的异噁唑化合物 | |
| WO2022253255A1 (en) | Fused heterocyclic derivatives | |
| US20220348592A1 (en) | Fused heterocyclic derivatives | |
| JP2022534960A (ja) | カプシド集合修飾因子としてのジアゼピノン誘導体 | |
| WO2020239864A1 (en) | Fused heterocycle derivatives as capsid assembly modulators | |
| EA047929B1 (ru) | Сочлененные гетероциклические производные | |
| JP2022535208A (ja) | 抗ウイルス剤としての縮合ヘテロ環誘導体 | |
| HK40066700A (zh) | 稠合杂环衍生物 | |
| US20240287070A1 (en) | Fused heterocyclic derivatives | |
| WO2022116998A1 (en) | Fused heterocyclic derivatives as hbv inhibitors | |
| HK40033068A (en) | Isoxazole compounds for the treatment of diseases associated with hbv infections | |
| HK40032660A (en) | Substituted pyrrolizine compounds as hbv replication inhibitors |